Stock AnalizZai Lab Ltd ZLAB
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
Zai Lab Ltd (ZLAB) is a healthcare company listed in the US with a market value of about $3.0B. In the twelve months to September 30, 2026 it had revenue of $442M and net income of -$198M, a net margin of -44.9%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 57% a year, a 5-year average ROIC of -37%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $442M | $460M | $399M | $267M | $215M | $144M | $49M | $13M | $129000 | — | — |
| Net income | -$198M | -$176M | -$257M | -$335M | -$443M | -$704M | -$269M | -$195M | -$139M | -$50M | -$38M |
| Free cash flow | -$163M | -$159M | -$221M | -$205M | -$392M | -$568M | -$226M | -$197M | -$108M | -$41M | -$34M |
| EPS (diluted) | $-1.78 | $-1.42 | $-2.08 | $-2.70 | $-3.58 | $-5.69 | $-2.17 | $-1.58 | $-1.12 | $-0.41 | $-0.30 |
| Net margin | -44.9% | -38.1% | -64.4% | -125.5% | -206.1% | -488.2% | -549.3% | -1502.3% | -107800.0% | — | — |
| ROIC | — | -24.0% | -28.4% | -45.2% | -37.9% | -50.2% | -25.4% | -64.2% | -54.2% | -21.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $34.12, 39% above the current price; targets range from $24.25 to $56.00; the consensus rating is “Strong buy”; expected EPS is $-1.88 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Zai Lab stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Zai Lab pay a dividend?
Not currently.
Is Zai Lab a good stock to buy?
We do not give buy or sell advice. Zai Lab scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.